HC Wainwright Has Optimistic Outlook of Myomo Q2 Earnings

Myomo, Inc. (NYSEAMERICAN:MYO) – Equities researchers at HC Wainwright lifted their Q2 2026 earnings estimates for Myomo in a note issued to investors on Friday, May 8th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.10). The consensus estimate for Myomo’s current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Myomo’s Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.24) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q4 2027 earnings at $0.02 EPS, FY2027 earnings at ($0.15) EPS, FY2028 earnings at $0.00 EPS and FY2029 earnings at $0.22 EPS.

Separately, Craig Hallum restated a “buy” rating on shares of Myomo in a report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Myomo currently has an average rating of “Buy” and an average price target of $7.67.

Myomo Trading Up 2.7%

Shares of MYO opened at $0.85 on Tuesday. Myomo has a twelve month low of $0.61 and a twelve month high of $3.69. The company has a market cap of $32.84 million, a P/E ratio of -2.36 and a beta of 1.39. The company has a current ratio of 3.30, a quick ratio of 2.93 and a debt-to-equity ratio of 0.98. The company’s fifty day simple moving average is $0.76 and its 200-day simple moving average is $0.85.

Insider Activity

In other Myomo news, Director Heather C. Getz bought 70,000 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $51,100.00. Following the acquisition, the director directly owned 111,754 shares in the company, valued at approximately $81,580.42. The trade was a 167.65% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Thomas F. Kirk bought 72,000 shares of the company’s stock in a transaction on Friday, March 13th. The shares were acquired at an average price of $0.71 per share, for a total transaction of $51,120.00. Following the completion of the acquisition, the director owned 553,857 shares in the company, valued at $393,238.47. This represents a 14.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have acquired 162,000 shares of company stock worth $116,220. 4.54% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Engineers Gate Manager LP grew its holdings in Myomo by 62.8% during the 2nd quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock worth $65,000 after acquiring an additional 11,614 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Myomo by 93.6% in the 3rd quarter. Bank of America Corp DE now owns 30,412 shares of the company’s stock valued at $27,000 after buying an additional 14,705 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Myomo in the 1st quarter valued at about $75,000. Invesco Ltd. bought a new stake in shares of Myomo in the 2nd quarter valued at about $37,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Myomo during the 2nd quarter worth approximately $38,000. 44.99% of the stock is currently owned by institutional investors.

Key Stories Impacting Myomo

Here are the key news stories impacting Myomo this week:

• Positive Sentiment: HC Wainwright lifted its FY2026 EPS estimate for Myomo to a smaller loss of $(0.24) from $(0.34), suggesting improved expected performance. Q3 Earnings Estimate for Myomo Issued By HC Wainwright
• Positive Sentiment: The firm also raised FY2027 EPS estimates to $(0.15) from $(0.22), FY2028 EPS to $0.00 from $(0.05), and FY2029 EPS to $0.22 from $0.16, reinforcing expectations that losses could narrow and profitability could eventually emerge. Myomo stock information
• Neutral Sentiment: HC Wainwright’s quarter-by-quarter updates were mixed but generally modestly improved, with Q2 2026 now at $(0.08), Q3 2026 at $(0.07), and Q4 2026 at $(0.02), indicating gradual progress rather than a major near-term turnaround.
• Neutral Sentiment: The estimates remain below breakeven in the near term, so investors may still view Myomo as a speculative growth story with execution risk.

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.